Sun Pharma announces 5-year sustained efficacy and safety results from pooled reSURFACE 1 and reSURFACE 2 extension studies for tildrakizumab (Ilumetri) in patients with moderate-to-severe plaque psoriasis

In patients treated with this IL-23 inhibitor at 100mg dose, clear or almost clear skin (PASI 90) was achieved by 65.9% patients and 32.8% achieved completely clear skin (PASI 100) at Week 244. Standard goal of treatment, a PASI 75 response, was achieved by 88.7% at Week 244.

Source:

Biospace Inc.